The thyroid cancer treatment market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. The increasing prevalence of thyroid cancer globally, along with the growing investment in the healthcare expenditure are expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and the rising middle-class population in the emerging economies on a global level. According to the data collected from the United Nations Department of Economic and Social Affairs, in 2020, the estimated elderly population aged above 65 accounted for 727 million and by 2050 the number is expected to get double to approximately 1,500 million.
The market is segmented based on treatment type into surgery, iodine therapy, external radiotherapy, thyroxin treatment, chemotherapy, and drugs, out of which, the drug segment is anticipated to grab the largest share by the end of 2021 on account of increased approval of thyroid cancer drugs in the market. Moreover, increasing initiative by the major players to develop better drugs in the global market is also projected to contribute to the growth of the segment during the forecast period.
On the basis of cancer type, the papillary thyroid cancer segment in the global thyroid cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that patients has witnessed high recovery rate in papillary thyroid cancer treatment. As a result, a considerable portion of the population with papillary thyroid cancer on a global level is expected to drive the growth of the market over the forecast period.
Based on end-user, the cancer diagnostic centres segment held the largest share in the global thyroid cancer treatment market on the back of increasing investment in research & development studies and growing concern and awareness for thyroid cancer treatment.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing elderly population and the rising investment in R&D for the innovation of new drugs and techniques for thyroid cancer treatment in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing healthcare investment, accompanied by the presence of leading healthcare service providers, and the increasing number of cancer patients in the region. Along with this, the countries in North America such as the United States is promoting cancer care for cancer patients, which is also expected to contribute to the market growth in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing rate of cancer is further expected to drive the demand for thyroid cancer treatment products in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global thyroid cancer treatment market on account of its proven success in terms of technology development and a high prevalence of cancer in the region. As per the analysis of the European Society for Medical Oncology, 2.7 million new cancer cases were registered in the European Union, with 1.3 million deaths in 2020.
The global Thyroid cancer treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global Thyroid cancer treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Rising prevalence of thyroid cancer and increasing elderly population are the key factors driving market growth.
The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.
Lack of awareness among the developing and under-developed countries and high cost of diagnosis are estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the increasing elderly population.
The major players dominating the Thyroid cancer treatment market are Sanofi S.A., Exelixis, Inc., Medtronic plc, Eisai Co., Ltd., Bayer AG, Novartis International AG, Pfizer Inc., Mylan N.V., Bristol Myers Squibbothers, and others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by treatment type, cancer type, end-user and region.
With respect to cancer type, the papillary thyroid cancer segment is anticipated to hold the largest market share owing to the surged up rate of recovery rate in papillary thyroid cancer treatment.
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization